Review



ctcs pd l1  (CellSearch inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    CellSearch inc ctcs pd l1
    Ongoing clinical trials of immunotherapy on liver cancer.
    Ctcs Pd L1, supplied by CellSearch inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctcs pd l1/product/CellSearch inc
    Average 86 stars, based on 1 article reviews
    ctcs pd l1 - by Bioz Stars, 2025-03
    86/100 stars

    Images

    1) Product Images from "Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment"

    Article Title: Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2024.1460282

    Ongoing clinical trials of immunotherapy on liver cancer.
    Figure Legend Snippet: Ongoing clinical trials of immunotherapy on liver cancer.

    Techniques Used: Transplantation Assay, Control, Concentration Assay, Comparison, Sequencing



    Similar Products

    pd l1 ctc  (Ficoll-Paque Pharmacia)
    86
    Ficoll-Paque Pharmacia pd l1 ctc
    Pd L1 Ctc, supplied by Ficoll-Paque Pharmacia, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd l1 ctc/product/Ficoll-Paque Pharmacia
    Average 86 stars, based on 1 article reviews
    pd l1 ctc - by Bioz Stars, 2025-03
    86/100 stars
    		  Buy from Supplier
    ctcs pd l1  (CellSearch inc)
    86
    CellSearch inc ctcs pd l1
    Ongoing clinical trials of immunotherapy on liver cancer.
    Ctcs Pd L1, supplied by CellSearch inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctcs pd l1/product/CellSearch inc
    Average 86 stars, based on 1 article reviews
    ctcs pd l1 - by Bioz Stars, 2025-03
    86/100 stars
    		  Buy from Supplier
    ctc subgroup expressing pd l1  (CellSearch inc)
    86
    CellSearch inc ctc subgroup expressing pd l1
    Ongoing clinical trials of immunotherapy on liver cancer.
    Ctc Subgroup Expressing Pd L1, supplied by CellSearch inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctc subgroup expressing pd l1/product/CellSearch inc
    Average 86 stars, based on 1 article reviews
    ctc subgroup expressing pd l1 - by Bioz Stars, 2025-03
    86/100 stars
    		  Buy from Supplier
    ctc pd l1 status  (Bruker Corporation)
    86
    Bruker Corporation ctc pd l1 status
    Ongoing clinical trials of immunotherapy on liver cancer.
    Ctc Pd L1 Status, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctc pd l1 status/product/Bruker Corporation
    Average 86 stars, based on 1 article reviews
    ctc pd l1 status - by Bioz Stars, 2025-03
    86/100 stars
    		  Buy from Supplier
    pd l1 ctcs  (KEYENCE)
    86
    KEYENCE pd l1 ctcs
    Ongoing clinical trials of immunotherapy on liver cancer.
    Pd L1 Ctcs, supplied by KEYENCE, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd l1 ctcs/product/KEYENCE
    Average 86 stars, based on 1 article reviews
    pd l1 ctcs - by Bioz Stars, 2025-03
    86/100 stars
    		  Buy from Supplier
    pd l1 ctcs  (CellSearch inc)
    86
    CellSearch inc pd l1 ctcs
    Ongoing clinical trials of immunotherapy on liver cancer.
    Pd L1 Ctcs, supplied by CellSearch inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd l1 ctcs/product/CellSearch inc
    Average 86 stars, based on 1 article reviews
    pd l1 ctcs - by Bioz Stars, 2025-03
    86/100 stars
    		  Buy from Supplier
    ctc pd l1  (ANGLE plc)
    86
    ANGLE plc ctc pd l1
    Baseline and <t> CTC, CTC PD-L1 </t> detection in the full patient population.
    Ctc Pd L1, supplied by ANGLE plc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ctc pd l1/product/ANGLE plc
    Average 86 stars, based on 1 article reviews
    ctc pd l1 - by Bioz Stars, 2025-03
    86/100 stars
    		  Buy from Supplier
    aneuploid pd ‑ l1 positive ctc cec  (Cytelligen Inc)
    86
    Cytelligen Inc aneuploid pd ‑ l1 positive ctc cec
    Baseline and <t> CTC, CTC PD-L1 </t> detection in the full patient population.
    Aneuploid Pd ‑ L1 Positive Ctc Cec, supplied by Cytelligen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/aneuploid pd ‑ l1 positive ctc cec/product/Cytelligen Inc
    Average 86 stars, based on 1 article reviews
    aneuploid pd ‑ l1 positive ctc cec - by Bioz Stars, 2025-03
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Ongoing clinical trials of immunotherapy on liver cancer.

    Journal: Frontiers in Immunology

    Article Title: Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment

    doi: 10.3389/fimmu.2024.1460282

    Figure Lengend Snippet: Ongoing clinical trials of immunotherapy on liver cancer.

    Article Snippet: NCT05810402 , Interventional , NA , Not yet recruiting , 60 , HCC, ICI, Liquid Biopsy , 1 Percentage of patients with CTCs-PD-L1+ by CellSearch ® technique 2 OS 3 PFS.

    Techniques: Transplantation Assay, Control, Concentration Assay, Comparison, Sequencing

    Baseline and CTC, CTC PD-L1 detection in the full patient population.

    Journal: Oncology Letters

    Article Title: Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs

    doi: 10.3892/ol.2024.14264

    Figure Lengend Snippet: Baseline and CTC, CTC PD-L1 detection in the full patient population.

    Article Snippet: Janning et al ( ) compared the efficiency of the EpCAM-based CellSearch ® detection system (Veridex, LLC) and the epitope-independent Parsortix ® system (ANGLE plc) in detecting CTC PD-L1, and the results demonstrated that tumor heterogeneity notably affected CTC PD-L1 detection, and the concordance of CTC PD-L1 detection with clinical puncture results.

    Techniques:

    CTC and CTC PD-L1 tests in patients with NSCLC. CTC counts in 40 patients with NSCLC with different (A) T, (B) N and (C) M stages. (D) CTC number in 40 patients with positive or negative PD-L1 expression in tissues. (E) PD-L1 levels in 40 patients with positive or negative CTC PD-L1 expression. Data are expressed as the mean ± standard deviation. ANOVA or t tests were used for analysis. *P<0.05; ****P<0.0001. CTCs, circulating tumor cells; PD-L1, programmed death-ligand 1; NSCLC, non-small cell lung cancer.

    Journal: Oncology Letters

    Article Title: Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs

    doi: 10.3892/ol.2024.14264

    Figure Lengend Snippet: CTC and CTC PD-L1 tests in patients with NSCLC. CTC counts in 40 patients with NSCLC with different (A) T, (B) N and (C) M stages. (D) CTC number in 40 patients with positive or negative PD-L1 expression in tissues. (E) PD-L1 levels in 40 patients with positive or negative CTC PD-L1 expression. Data are expressed as the mean ± standard deviation. ANOVA or t tests were used for analysis. *P<0.05; ****P<0.0001. CTCs, circulating tumor cells; PD-L1, programmed death-ligand 1; NSCLC, non-small cell lung cancer.

    Article Snippet: Janning et al ( ) compared the efficiency of the EpCAM-based CellSearch ® detection system (Veridex, LLC) and the epitope-independent Parsortix ® system (ANGLE plc) in detecting CTC PD-L1, and the results demonstrated that tumor heterogeneity notably affected CTC PD-L1 detection, and the concordance of CTC PD-L1 detection with clinical puncture results.

    Techniques: Expressing, Standard Deviation

    Correlation between CTC PD-L1 and tissue PD-L1 expression. (A) Correlation analysis between CTC count and PD-L1 expression in tissues. (B) Receiver operating characteristic analysis of CTC PD-L1 and PD-L1 expression in tissues. CTCs, circulating tumor cells; PD-L1, programmed death-ligand 1; AUC, area under curve; 95% CI, 95% confidence interval.

    Journal: Oncology Letters

    Article Title: Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs

    doi: 10.3892/ol.2024.14264

    Figure Lengend Snippet: Correlation between CTC PD-L1 and tissue PD-L1 expression. (A) Correlation analysis between CTC count and PD-L1 expression in tissues. (B) Receiver operating characteristic analysis of CTC PD-L1 and PD-L1 expression in tissues. CTCs, circulating tumor cells; PD-L1, programmed death-ligand 1; AUC, area under curve; 95% CI, 95% confidence interval.

    Article Snippet: Janning et al ( ) compared the efficiency of the EpCAM-based CellSearch ® detection system (Veridex, LLC) and the epitope-independent Parsortix ® system (ANGLE plc) in detecting CTC PD-L1, and the results demonstrated that tumor heterogeneity notably affected CTC PD-L1 detection, and the concordance of CTC PD-L1 detection with clinical puncture results.

    Techniques: Expressing

    Prognostic value of baseline characteristics and CTCs in 26 patients with NSCLC. Association between PFS and (A) tissue PD-L1 levels, (B) baseline characteristics, CTCs and CTC PD-L1, and (C) other blood indicators. CTCs, circulating tumor cells; NSCLC, non-small cell lung cancer; PFS, progression-free survival; PD-L1, programmed death-ligand 1; SQC, squamous-cell carcinoma; ADC, adenocarcinoma; PTL, platelet; SIS, systemic inflammatory score; RDW, red blood cell distribution width; WBC, white blood cell; HB, hemoglobin; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-mononuclear ratio; CEA, carcinoembryonic antigen; CYFRA-19, cytokeratin 19; PNI, prognostic nutritional index.

    Journal: Oncology Letters

    Article Title: Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs

    doi: 10.3892/ol.2024.14264

    Figure Lengend Snippet: Prognostic value of baseline characteristics and CTCs in 26 patients with NSCLC. Association between PFS and (A) tissue PD-L1 levels, (B) baseline characteristics, CTCs and CTC PD-L1, and (C) other blood indicators. CTCs, circulating tumor cells; NSCLC, non-small cell lung cancer; PFS, progression-free survival; PD-L1, programmed death-ligand 1; SQC, squamous-cell carcinoma; ADC, adenocarcinoma; PTL, platelet; SIS, systemic inflammatory score; RDW, red blood cell distribution width; WBC, white blood cell; HB, hemoglobin; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-mononuclear ratio; CEA, carcinoembryonic antigen; CYFRA-19, cytokeratin 19; PNI, prognostic nutritional index.

    Article Snippet: Janning et al ( ) compared the efficiency of the EpCAM-based CellSearch ® detection system (Veridex, LLC) and the epitope-independent Parsortix ® system (ANGLE plc) in detecting CTC PD-L1, and the results demonstrated that tumor heterogeneity notably affected CTC PD-L1 detection, and the concordance of CTC PD-L1 detection with clinical puncture results.

    Techniques:

    Patient characteristics and CTC, CTC PD-L1 after combination treatment.

    Journal: Oncology Letters

    Article Title: Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs

    doi: 10.3892/ol.2024.14264

    Figure Lengend Snippet: Patient characteristics and CTC, CTC PD-L1 after combination treatment.

    Article Snippet: Janning et al ( ) compared the efficiency of the EpCAM-based CellSearch ® detection system (Veridex, LLC) and the epitope-independent Parsortix ® system (ANGLE plc) in detecting CTC PD-L1, and the results demonstrated that tumor heterogeneity notably affected CTC PD-L1 detection, and the concordance of CTC PD-L1 detection with clinical puncture results.

    Techniques:

    Prognostic value of blood indicators in 11 patients with NSCLC following treatment. (A) Association between PFS and blood indicators in 11 patients with NSCLC. Association between PFS and (B) treatment maintenance or (C) tumor shrinkage. (D) CTC PD-L1 expression following treatment with ICIs in combination with platinum-containing compounds. (E) Tumor metastasis. NSCLC, non-small cell lung cancer; PFS, progression-free survival; PD-L1, programmed death-ligand 1; CTCs, circulating tumor cells; ICIs, immune checkpoint inhibitors; PLT, platelet; HB, hemoglobin; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-mononuclear ratio; CEA, carcinoembryonic antigen; CYFRA-19, cytokeratin 19; PNI, prognostic nutritional index; CK, cytokeratin.

    Journal: Oncology Letters

    Article Title: Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs

    doi: 10.3892/ol.2024.14264

    Figure Lengend Snippet: Prognostic value of blood indicators in 11 patients with NSCLC following treatment. (A) Association between PFS and blood indicators in 11 patients with NSCLC. Association between PFS and (B) treatment maintenance or (C) tumor shrinkage. (D) CTC PD-L1 expression following treatment with ICIs in combination with platinum-containing compounds. (E) Tumor metastasis. NSCLC, non-small cell lung cancer; PFS, progression-free survival; PD-L1, programmed death-ligand 1; CTCs, circulating tumor cells; ICIs, immune checkpoint inhibitors; PLT, platelet; HB, hemoglobin; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-mononuclear ratio; CEA, carcinoembryonic antigen; CYFRA-19, cytokeratin 19; PNI, prognostic nutritional index; CK, cytokeratin.

    Article Snippet: Janning et al ( ) compared the efficiency of the EpCAM-based CellSearch ® detection system (Veridex, LLC) and the epitope-independent Parsortix ® system (ANGLE plc) in detecting CTC PD-L1, and the results demonstrated that tumor heterogeneity notably affected CTC PD-L1 detection, and the concordance of CTC PD-L1 detection with clinical puncture results.

    Techniques: Expressing